Literature DB >> 32205136

Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.

Joep J de Jong1, Joost L Boormans1, Bas W G van Rhijn2, Roland Seiler3, Stephen A Boorjian4, Badrinath Konety5, Trinity J Bivalacqua6, Thomas Wheeler7, Robert S Svatek8, James Douglas9, Jonathan Wright10, Marc Dall'Era11, Simon J Crabb12, Jason A Efstathiou13, Michiel S van der Heijden14, Kent W Mouw15, David T Miyamoto16, Yair Lotan17, Peter C Black18, Ewan A Gibb19, Sima P Porten20.   

Abstract

Muscle-invasive bladder cancer (MIBC) is a sex-biased cancer with a higher incidence in men but worse outcomes in women. The root cause behind these observations remains unclear. To investigate whether sex-specific tumor biology could explain the differences in clinical behavior of MIBC, we analyzed the transcriptome profiles from transurethral resected bladder tumors of 1000 patients. Female tumors expressed higher levels of basal- and immune-associated genes, while male tumors expressed higher levels of luminal markers. Using molecular subtyping, we found that the rates of the basal/squamous subtype were higher in females than in males. Males were enriched with tumors of the luminal papillary (LumP) and neuroendocrine-like subtypes. Male MIBC tumors had higher androgen response activity across all luminal subtypes and male patients with LumP tumors were younger. Taken together, these data confirm differences in molecular subtypes based on sex. The role of the androgen response pathway in explaining subtype differences between men and women should be studied further. PATIENT
SUMMARY: We explored the sex-specific biology of bladder cancer in 1000 patients and found that women had more aggressive cancer with higher immune activity. Men tended toward less aggressive tumors that showed male hormone signaling, suggesting that male hormones may influence the type of bladder cancer that a patient develops.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Gene expression; Molecular subtypes; Sex specific

Mesh:

Year:  2020        PMID: 32205136     DOI: 10.1016/j.euo.2020.02.010

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  10 in total

1.  Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.

Authors:  Qing Liu; Bosen You; Jialin Meng; Chi-Ping Huang; Guanglu Dong; Ronghao Wang; Fuju Chou; Shan Gao; Chawnshang Chang; Shuyuan Yeh; Wanhai Xu
Journal:  Cancer Gene Ther       Date:  2022-08-01       Impact factor: 5.854

Review 2.  [Gender-associated differences in bladder cancer].

Authors:  Georgios Gakis; Dorothea Weckermann
Journal:  Urologie       Date:  2022-08-18

3.  Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.

Authors:  Yadong Guo; Zongtai Zheng; Wentao Zhang; Shiyu Mao; Fuhan Yang; Wei Li; Yang Yan; Xudong Yao
Journal:  Ther Adv Med Oncol       Date:  2022-06-28       Impact factor: 5.485

4.  Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study.

Authors:  Leslie K Ballas; Stephanie Navarro; Chunqiao Luo; Croix C Fossum; Albert Farias; Siamak Daneshmand; Susan Groshen
Journal:  Cancer Med       Date:  2021-03-28       Impact factor: 4.452

Review 5.  Genome-Wide Sex and Gender Differences in Cancer.

Authors:  Camila M Lopes-Ramos; John Quackenbush; Dawn L DeMeo
Journal:  Front Oncol       Date:  2020-11-23       Impact factor: 6.244

Review 6.  Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity.

Authors:  Charles T Lutz; Lydia Livas; Steven R Presnell; Morgan Sexton; Peng Wang
Journal:  J Clin Med       Date:  2021-11-04       Impact factor: 4.964

Review 7.  The impact of biological sex on diseases of the urinary tract.

Authors:  Léa Deltourbe; Livia Lacerda Mariano; Teri N Hreha; David A Hunstad; Molly A Ingersoll
Journal:  Mucosal Immunol       Date:  2022-07-22       Impact factor: 8.701

8.  Androgen Receptor Regulates CD44 Expression in Bladder Cancer.

Authors:  Joseph L Sottnik; Lauren Vanderlinden; Molishree Joshi; Ana Chauca-Diaz; Charles Owens; Donna E Hansel; Colin Sempeck; Debashis Ghosh; Dan Theodorescu
Journal:  Cancer Res       Date:  2021-03-09       Impact factor: 13.312

9.  Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer.

Authors:  Alejandra Bernardini; Marta Dueñas; María Cruz Martín-Soberon; Carolina Rubio; Cristian Suarez-Cabrera; Raquel Ruiz-Palomares; Ester Munera-Maravilla; Sara Lázaro; Iris Lodewijk; Daniel Rueda; David Gómez-Sánchez; Teresa Alonso-Gordoa; Javier Puente; Álvaro Pinto; Pilar González-Peramato; Carlos Aguado; Mercedes Herrera; Flora López; Victor M G Martinez; Lucía Morales; Daniel Castellano; Jesús M Paramio; Guillermo de Velasco
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

10.  Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.

Authors:  Carina Bernardo; Fátima L Monteiro; Inês Direito; Francisco Amado; Vera Afreixo; Lúcio L Santos; Luisa A Helguero
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.